argenx reports third-quarter results as argenx stock trades at EUR 782.90
Published on 10/24/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults and upcoming dates
- On October 22, 2026, argenx reported $1.7 billion in third-quarter product net sales.
- argenx stock traded at EUR 782.90 at 10:56 a.m. CEST on October 24, 2026.
- The next Xetra session is scheduled for October 26, 2026.
On October 22, 2026, argenx SE reported third-quarter 2026 results and a business update. The company said global product net sales reached $1.7 billion in the third quarter, up 54 percent from the same period a year earlier.
At 10:56 a.m. CEST on October 24, 2026, argenx stock traded at EUR 782.90 in weekend trading at Lang & Schwarz. The bid was EUR 781.20 and the ask was EUR 784.60.
Company update
The company reported third-quarter operating profit of $486 million and profit for the period of $506 million. Product net sales for the first nine months of 2026 totaled $4.5 billion. The figures were reported in the company’s unaudited interim financial statements for the period ended September 30, 2026.
argenx said it had submitted a supplemental biologics license application for VYVGART in ocular myasthenia gravis to the U.S. Food and Drug Administration. It also said top-line results from the Phase 3 EMPASSION study in multifocal motor neuropathy are expected in December 2026. The release stated that combined research and development and selling, general and administrative expenses are expected to be approximately $4 billion for 2026, including costs related to the Forte transaction.
Market context: Market report AEX.
Next Xetra session
The next Xetra session is scheduled for October 26, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of argenx stock.
